CD40 and neoplasm: Antibodies stimulating CD40 signaling (agonistic CD40 mAb) show promising results with manageable toxicities in several clinical trials.1,2 CD40-activating immunotherapy primarily occurs through stimulation of dendritic cells (DCs) that subsequently prime T-cells via tumor antigen presentation.